Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.810
-0.100 (-2.56%)
Nov 21, 2024, 11:03 AM EST - Market open
Xenetic Biosciences Revenue
Xenetic Biosciences had revenue of $614.24K in the quarter ending September 30, 2024, with 0.50% growth. This brings the company's revenue in the last twelve months to $2.52M, up 7.15% year-over-year. In the year 2023, Xenetic Biosciences had annual revenue of $2.54M with 48.80% growth.
Revenue (ttm)
$2.52M
Revenue Growth
+7.15%
P/S Ratio
2.44
Revenue / Employee
$630,857
Employees
4
Market Cap
5.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
Dec 31, 2022 | 1.71M | 546.23K | 47.06% |
Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
Dec 31, 2019 | 17.07K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cutera | 155.21M |
Healthcare Triangle | 16.57M |
Syra Health | 7.74M |
Intelligent Bio Solutions | 3.19M |
Biora Therapeutics | 892.00K |
XBIO News
- 3 hours ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - Accesswire
- 8 days ago - Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - Accesswire
- 9 days ago - Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Accesswire
- 14 days ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 4 weeks ago - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - Accesswire
- 5 weeks ago - Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Accesswire